Topic collections
Study selection and assessment: randomised controlled trials (RCTs), in any language, that assessed the use of viscosupplementation for treatment of osteoarthritis of the knee, compared with placebo or active treatment, and reported relevant outcomes. 2 reviewers independently assessed included trials for methodological quality using the Jadad scale. 
MAIN RESULTS
63 RCTs met the selection criteria; 37 RCTs compared an HA product with placebo. Compared with placebo, HA improved pain on weight bearing at 1-4 weeks, 5-13 weeks, and 14-26 weeks after the last injection (table) . HA improved the Lequesne Index at 1-4 weeks and 5-13 weeks and WOMAC function at 5-13 weeks (table) . Efficacy varied by type of HA product (see www.evidence-basedmedicine.com for detailed results). Hyalgan and Hylan G-F 20 both significantly reduced pain on weight bearing more than placebo at all 3 time periods, although the effect size was at least twice as great with the latter product. Artz significantly reduced pain at 5-13 weeks but not at the other 2 time periods. Other individual products were not extensively studied. In direct comparisons between Hylan G-F 20 and a hyaluronan product, the difference in pain on weight bearing was not significant at 1-4 weeks but favoured the Hylan product at 5-13 weeks. This review also presented data comparing HA with intraarticular corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and several other therapies. However, because of variability across trials, meta-analysis was not generally possible.
CONCLUSION
In patients with osteoarthritis of the knee, viscosupplementation, with either hyaluronan or hylan products, reduces pain and improves function for up to 26 weeks. Methodologically, the review suffers only from the absence of a description of the homogeneity of the patients. The results show partly why some clinicians remain sceptical about hyaluranon infusions.
1 The absolute improvement in pain was fairly small between treatment and placebo, and functional results and overall WOMAC improvement were inconsistent. Response peaked at 5-13 weeks and declined therafter without a consistent superiority of any brand. What remains unanswered from the study are the other 2 important clinical questions about viscosupplementation.
